Piramal Pharma shares recover from lows, surge 3% after Co affirms FY26 guidance

Segment-wise, the contract development and manufacturing organisation (CDMO) business saw the steepest impact, with revenue declining 9% year-on-year to ₹1,166 crore from ₹1,278 crore.

Leave a Reply

Your email address will not be published. Required fields are marked *